Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A seat for a vehicle cab comprises a seat structure, the seat structure defining an internal volume and being configured to be attached to a floor of the vehicle cab; an energy storage system, the energy storage system being located in the internal volume of the seat structure and being configured to provide electric power; and a tray, configured to rest on the floor of the vehicle cab, the energy storage system resting on the tray. Furthermore, the tray and the energy storage system are devoid of attachment to the seat structure.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having DV90 < 5 µm and Dv50< 1 µm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A magnetic resonance detection (MRD) system for and methods of detecting and classifying multiple chemical substances is disclosed. In one example, the presently disclosed MRD system is a nuclear quadrupole resonance (NQR) detection system that provides multi-frequency operation for substantially full coverage of the explosive NQR spectrum using a broadband transmit/receive (T/R) switch (or duplexer) and a single multi-frequency radio frequency (RF) transducer. More particularly, the MRD system provides a frequency-agile system that can operate over a wide band of frequencies or wavelengths. Further, a method of detecting and classifying various chemical substances is provided that includes pulse sequencing with “frequency hopping,” phase cycling for reducing or substantially eliminating background noise, and/or a process of mitigating amplitude modulation (AM) radio interference.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A direct air capture (DAC) system for removal of carbon dioxide from ambient air has a reaction chamber having an air intake opening and an air exhaust opening, an air movement mechanism positioned to move air from outside through the reaction chamber, utilizing the air intake and the air exhaust openings, and a mechanism introducing sodium hydroxide into the reaction chamber. Carbon dioxide in the air moved through the reaction chamber interacts chemically with the sodium hydroxide, producing sodium carbonate and water.

Abstract: Provided herein are pharmaceutical compositions comprising methylnaltrexone, lauryl sulfate or docusate, and at least one of an oil, a surfactant or a cosolvent, wherein the methylnaltrexone and lauryl sulfate or docusate are present as an ion pair. The pharmaceutical compositions may further comprise a surfactant so as to provide self-emulsifying methylnaltrexone delivery systems.

Abstract: A magnetic resonance detection (MRD) system for and methods of detecting and classifying multiple chemical substances is disclosed. In one example, the presently disclosed MRD system is a nuclear quadrupole resonance (NQR) detection system that provides multi-frequency operation for substantially full coverage of the explosive NQR spectrum using a broadband transmit/receive (T/R) switch (or duplexer) and a single multi-frequency radio frequency (RF) transducer. More particularly, the MRD system provides a frequency-agile system that can operate over a wide band of frequencies or wavelengths. Further, a method of detecting and classifying various chemical substances is provided that includes pulse sequencing with “frequency hopping,” phase cycling for reducing or substantially eliminating background noise, and/or a process of mitigating amplitude modulation (AM) radio interference.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Abstract: The invention relates to a vaporization injector for a gas chromatograph, said injector comprising a structure (11) mounted in a detachable manner on the gas chromatograph body and including the sample introduction means, the vaporization chamber and pneumatic connections for feeding the carrier gas to the vaporization chamber and to the septum purge means, as well as pneumatic connections for evacuating the splitted sample and carrier gases.

Abstract: Amorphous solid-state form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2? angles of 6.9-7.1, 9.4, 10.6-10.7, and 13.4-13.7°±0.2°, and a diffuse halo pattern at 11-30°; and (b) a DSC (differential scanning calorimetry) melting peak at about 267-272° C. The amorphous solid is prepared by rapid precipitation from a saturated or supersaturated solution of besifloxacin free base in a solvent comprising at least benzyl alcohol.

Abstract: A topical pharmaceutical composition comprising a pharmaceutical active and a polymer of general formula I or general formula II wherein Ck is a saturated or unsaturated, five, six or seven-membered ring; R is a C1-C3alkyl; n is 1, 2, 3, 4 or 5 and m provides a number average molecular weight of the polymer of from 2000 to 80,000.

Abstract: The invention relates to a vaporization injector for a gas chromatograph, said injector comprising a structure (11) mounted in a detachable manner on the gas chromatograph body and including the sample introduction means, the vaporization chamber and pneumatic connections for feeding the carrier gas to the vaporization chamber and to the septum purge means, as well as pneumatic connections for evacuating the splitted sample and carrier gases.

Abstract: A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-ylamino)-2-(4-methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2? angles of 7.44, 14.80, 16.64, and 23.04±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis.

Abstract: Amorphous solid-state form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2? angles of 6.9-7.1, 9.4, 10.6-10.7, and 13.4-13.7°±0.2°, and a diffuse halo pattern at 11-30°; and (b) a DSC (differential scanning calorimetry) melting peak at about 267-272° C. The amorphous solid is prepared by rapid precipitation from a saturated or supersaturated solution of besifloxacin free base in a solvent comprising at least benzyl alcohol.

Abstract: A topical pharmaceutical formulation comprising 0.5 ppm to 1000 ppm of a tertiary amine oxide of general formula I wherein R1 is a C8-C18alkyl, and R2 and R3 are independently selected from a C1-C4alkyl or C1-C4hydroxyalkyl. The tertiary amine oxide functions as a preservative or enhances the preservative efficacy in such formulations developed for topical administration. In particular, the topical formulation is an ophthalmic composition.

Abstract: An aqueous ophthalmic composition comprising a branched, glycerol monoalkyl compound and a fatty acid monoester. The fatty acid monoester comprises an aliphatic fatty acid portion having six to fourteen carbon atoms and an aliphatic hydroxyl portion. The composition will also have an osmolality in a range from 200 mOsmol/kg to 400 mOsmol/kg. The invention is also directed to a method of inhibiting the formation of foam in an aqueous ophthalmic composition that includes a surfactant as well as to a method of enhancing the biocidal efficacy of an aqueous ophthalmic composition containing a fatty acid monoester.

Abstract: A method of disinfecting, cleaning or packaging a contact lens by contacting the lens with an ophthalmically acceptable lens care composition. The composition comprises a fatty acid monoester and a cationic antimicrobial component. The fatty acid monoester comprises an aliphatic fatty acid portion having six to fourteen carbon atoms, and an aliphatic hydroxyl portion. The invention is also directed to an ophthalmically acceptable lens care composition comprising a fatty acid monoester and a cationic antimicrobial component.